Eurazeo’s Nov Santé Actions Non Cotées Fund makes first growth equity deal in Kinvent

Kinvent is a connected sensor provider for physical therapy.

  • This transaction is a part of a new equity financing round of €16m
  • Eurazeo is a European investment group
  • The firm €33.5bn in diversified assets under management

The Nov Santé Actions Non Cotées Fund, managed by Eurazeo, has finalised its first growth equity investment in Kinvent, acquiring a minority stake alongside the founder and existing minority shareholders.

This transaction is a part of a new equity financing round of €16 million.

Montpellier, France-based Kinvent is a connected sensor provider for physical therapy. Its services are used by over 14,000 physiotherapists operating in 68 countries globally.

Kinvent is planning to upscale, bolster its positions in its core markets and enter new markets, including the US, according to a release.

Nov Santé Actions Non Cotées was the leading investor, alongside the existing investors.

“Nearly three years after launching the fund and starting out in development capital, we are beginning a new chapter having struck our first Growth Equity deal,” said Arnaud Vincent, MD of the Nov Santé Actions Non Cotées fund. “This investment fits perfectly with the strategy pursued by Nov Santé Actions Non Cotées—to increase the digitalisation of the healthcare profession and accelerate the transformation of SMEs in France and Europe.”

Eurazeo is a European investment group with €33.5 billion in diversified assets under management. It has offices in Paris, New York, London, Frankfurt, Berlin, Milan, Madrid, Luxembourg, Shanghai, Seoul, Singapore and Sao Paulo.